194 related articles for article (PubMed ID: 24473773)
1. SIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation.
Pazienza V; Borghesan M; Mazza T; Sheedfar F; Panebianco C; Williams R; Mazzoccoli G; Andriulli A; Nakanishi T; Vinciguerra M
Aging (Albany NY); 2014 Jan; 6(1):35-47. PubMed ID: 24473773
[TBL] [Abstract][Full Text] [Related]
2. MacroH2A1 isoforms are associated with epigenetic markers for activation of lipogenic genes in fat-induced steatosis.
Podrini C; Koffas A; Chokshi S; Vinciguerra M; Lelliott CJ; White JK; Adissu HA; Williams R; Greco A
FASEB J; 2015 May; 29(5):1676-87. PubMed ID: 25526730
[TBL] [Abstract][Full Text] [Related]
3. Splicing regulates NAD metabolite binding to histone macroH2A.
Kustatscher G; Hothorn M; Pugieux C; Scheffzek K; Ladurner AG
Nat Struct Mol Biol; 2005 Jul; 12(7):624-5. PubMed ID: 15965484
[TBL] [Abstract][Full Text] [Related]
4. Immunopositivity for histone macroH2A1 isoforms marks steatosis-associated hepatocellular carcinoma.
Rappa F; Greco A; Podrini C; Cappello F; Foti M; Bourgoin L; Peyrou M; Marino A; Scibetta N; Williams R; Mazzoccoli G; Federici M; Pazienza V; Vinciguerra M
PLoS One; 2013; 8(1):e54458. PubMed ID: 23372727
[TBL] [Abstract][Full Text] [Related]
5. miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.
Long JK; Dai W; Zheng YW; Zhao SP
Mol Med; 2019 Jun; 25(1):26. PubMed ID: 31195981
[TBL] [Abstract][Full Text] [Related]
6. DNA Hypomethylation and Histone Variant macroH2A1 Synergistically Attenuate Chemotherapy-Induced Senescence to Promote Hepatocellular Carcinoma Progression.
Borghesan M; Fusilli C; Rappa F; Panebianco C; Rizzo G; Oben JA; Mazzoccoli G; Faulkes C; Pata I; Agodi A; Rezaee F; Minogue S; Warren A; Peterson A; Sedivy JM; Douet J; Buschbeck M; Cappello F; Mazza T; Pazienza V; Vinciguerra M
Cancer Res; 2016 Feb; 76(3):594-606. PubMed ID: 26772755
[TBL] [Abstract][Full Text] [Related]
7. Deletion of SIRT1 from hepatocytes in mice disrupts lipin-1 signaling and aggravates alcoholic fatty liver.
Yin H; Hu M; Liang X; Ajmo JM; Li X; Bataller R; Odena G; Stevens SM; You M
Gastroenterology; 2014 Mar; 146(3):801-11. PubMed ID: 24262277
[TBL] [Abstract][Full Text] [Related]
8. Down-Regulation of SIRT1 Expression by mir-23b Contributes to Lipid Accumulation in HepG2 Cells.
Borji M; Nourbakhsh M; Shafiee SM; Owji AA; Abdolvahabi Z; Hesari Z; Ilbeigi D; Seiri P; Yousefi Z
Biochem Genet; 2019 Aug; 57(4):507-521. PubMed ID: 30697640
[TBL] [Abstract][Full Text] [Related]
9. LB100 ameliorates nonalcoholic fatty liver disease
Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
[TBL] [Abstract][Full Text] [Related]
10. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
[TBL] [Abstract][Full Text] [Related]
11. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
12. Dioscin alleviates non-alcoholic fatty liver disease through adjusting lipid metabolism via SIRT1/AMPK signaling pathway.
Yao H; Tao X; Xu L; Qi Y; Yin L; Han X; Xu Y; Zheng L; Peng J
Pharmacol Res; 2018 May; 131():51-60. PubMed ID: 29574225
[TBL] [Abstract][Full Text] [Related]
13. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
[TBL] [Abstract][Full Text] [Related]
14. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans.
Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X
EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141
[TBL] [Abstract][Full Text] [Related]
15. Ginsenoside Rb2 Alleviates Hepatic Lipid Accumulation by Restoring Autophagy via Induction of Sirt1 and Activation of AMPK.
Huang Q; Wang T; Yang L; Wang HY
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28534819
[TBL] [Abstract][Full Text] [Related]
16. Resveratrol Ameliorates Lipid Droplet Accumulation in Liver Through a SIRT1/ ATF6-Dependent Mechanism.
Zhou R; Yi L; Ye X; Zeng X; Liu K; Qin Y; Zhang Q; Mi M
Cell Physiol Biochem; 2018; 51(5):2397-2420. PubMed ID: 30537742
[TBL] [Abstract][Full Text] [Related]
17. QKI-mediated alternative splicing of the histone variant MacroH2A1 regulates cancer cell proliferation.
Novikov L; Park JW; Chen H; Klerman H; Jalloh AS; Gamble MJ
Mol Cell Biol; 2011 Oct; 31(20):4244-55. PubMed ID: 21844227
[TBL] [Abstract][Full Text] [Related]
18. SIRT1 activation by methylene blue, a repurposed drug, leads to AMPK-mediated inhibition of steatosis and steatohepatitis.
Shin SY; Kim TH; Wu H; Choi YH; Kim SG
Eur J Pharmacol; 2014 Mar; 727():115-24. PubMed ID: 24486702
[TBL] [Abstract][Full Text] [Related]
19. OXPHOS-Mediated Induction of NAD+ Promotes Complete Oxidation of Fatty Acids and Interdicts Non-Alcoholic Fatty Liver Disease.
Akie TE; Liu L; Nam M; Lei S; Cooper MP
PLoS One; 2015; 10(5):e0125617. PubMed ID: 25933096
[TBL] [Abstract][Full Text] [Related]
20. Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver.
Salomone F; Barbagallo I; Godos J; Lembo V; Currenti W; Cinà D; Avola R; D'Orazio N; Morisco F; Galvano F; Li Volti G
Nutrients; 2017 Sep; 9(10):. PubMed ID: 28973994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
